Company / Financials
Catalyst Pharmaceuticals Partners, Inc. Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$589.0M
FY2025 · +19.8% YoY
Net Income
$214.3M
FY2025 · +30.8% YoY
Profit Margin
36.4%
FY2025 · net income / revenue
ROE
22.5%
FY2025 · return on equity
Total Assets
$1.1B
FY2025
Total Debt
-
FY2025
Equity
$954.3M
FY2025
ROA
19.4%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 4.78 (safe zone, above 2.9 threshold)
- Strong profit margin: 33.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$589.0M+19.8% YoYNet Income HistoryProfit after all expenses and taxes$214.3M+30.8% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$87.3M+26.7% YoYOperating Income HistoryProfit from core business operations before interest and taxes$257.8M+32.1% YoYSG&A Expense HistorySelling, general, and administrative expenses$193.8M+9.0% YoYR&D Expense HistoryResearch and development spending$12.7M+0.5% YoYIncome Tax HistoryTotal income tax expense$69.2M+32.1% YoYEPS (Basic) HistoryBasic earnings per share$1.75+26.8% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles$1.68+28.2% YoYShares Outstanding HistoryWeighted average diluted shares outstanding122.5M+1.4% YoY